Single dose of Glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses

Virology Journal

Volumn 10, Issue , 2013, Pages

  Iyer, Arun V ^a,c   Pahar, Bapi ^b   Chouljenko, Vladimir N ^a   Walker, Jason D ^a   Stanfield, Brent ^a   Kousoulas, Konstantin G ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c BOEHRINGER INGELHEIM VETMEDICA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN B; GLYCOPROTEIN D; GLYCOPROTEIN K; LIVE VACCINE; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME SPECIFICITY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT DURATION; VACCINATION; VAGINITIS; VIRUS ATTENUATION;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MUS;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VIRAL PROTEINS;

EID: 84886229556     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-317     Document Type: Article

References (51)

1. The genome sequence of herpes simplex virus type 2. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ, J Virol 1998 72 2010 2021 9499055 (Pubitemid 28100755)
2. Nongenital herpes simplex virus. Usatine RP, Tinitigan R, Am Fam Physician 2010 82 1075 1082 21121552
3. The herpes simplex virus type 1 (HSV-1) glycoprotein K(gK) is essential for viral corneal spread and neuroinvasiveness. David AT, Baghian A, Foster TP, Chouljenko VN, Kousoulas KG, Curr Eye Res 2008 33 455 467 10.1080/ 02713680802130362 18568883 (Pubitemid 351998844)
4. Genital herpes. Gupta R, Warren T, Wald A, Lancet 2007 370 2127 2137 10.1016/S0140-6736(07)61908-4 18156035 (Pubitemid 350296304)
5. Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes? Mertz GJ, Rosenthal SL, Stanberry LR, Sex Transm Dis 2003 30 801 802 10.1097/01.OLQ.0000093080.55201.D1 14520182 (Pubitemid 37229493)
6. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Roberts CM, Pfister JR, Spear SJ, Sex Transm Dis 2003 30 797 800 10.1097/01.OLQ.0000092387.58746.C7 14520181 (Pubitemid 37229492)
7. Herpes simplex virus type 1 is the main cause of genital herpes in women of Natal, Brazil. Pereira VS, Moizeis RN, Fernandes TA, Araujo JM, Meissner RV, Fernandes JV, Eur J Obstet Gynecol Reprod Biol 2012 161 190 193 10.1016/j.ejogrb.2011.12.006 22424592
8. The family herpesviridae: a brief introduction. Pellet PE, Roizman B, Fields' virology. Volume 2 Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, Fields BN, Knipe DM, Howley PM, 5 2007 2480 2499
9. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Fisman DN, Lipsitch M, Hook EW 3rd, Goldie SJ, Sex Transm Dis 2002 29 608 622 10.1097/00007435-200210000-00008 12370529
10. Recent progress in herpes simplex virus immunobiology and vaccine research. Koelle DM, Corey L, Clin Microbiol Rev 2003 16 96 113 10.1128/CMR.16.1.96-113.2003 12525427 (Pubitemid 36114709)
11. HSV-2 vaccine: Current state and insights into development of a vaccine that targets genital mucosal protection. Roth K, Ferreira VH, Kaushic C, Microb Pathog 2013 58 45 54 23159485
12. The potential impact of a prophylactic herpes simplex vaccine. Rupp R, Bernstein DI, Expert Opin Emerg Drugs 2008 13 41 52 10.1517/14728214.13.1.41 18321147 (Pubitemid 351448701)
13. The challenge of developing a herpes simplex virus 2 vaccine. Dropulic LK, Cohen JI, Expert Rev Vaccines 2012 11 1429 1440 10.1586/erv.12.129 23252387
14. Efficacy results of a trial of a herpes simplex vaccine. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, et al. N Engl J Med 2012 366 34 43 10.1056/NEJMoa1103151 22216840
15. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM, J Virol 2008 82 8431 8441 10.1128/JVI.00551-08 18562543
16. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, et al. J Virol 2012 86 4586 4598 10.1128/JVI.07203-11 22318147
17. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, Kern ER, Kemble GM, Spaete RR, Vaccine 2005 23 5424 5431 10.1016/j.vaccine.2005.02.028 15950327 (Pubitemid 41579315)
18. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. van Lint AL, Torres-Lopez E, Knipe DM, Virology 2007 368 227 231 10.1016/j.virol.2007.08. 030 17915278 (Pubitemid 350016230)
19. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Dudek T, Mathews LC, Knipe DM, Virology 2008 372 165 175 10.1016/j.virol.2007.10.014 18006033 (Pubitemid 351215459)
20. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI, Vaccine 2008 26 4034 4040 10.1016/j.vaccine.2008.05.022 18565628
21. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Da Costa XJ, Morrison LA, Knipe DM, Virology 2001 288 256 263 10.1006/viro.2001.1094 11601897 (Pubitemid 32929905)
22. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B, PLoS One 2011 6 17748 10.1371/journal.pone.0017748 21412438
23. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F, J Virol 2011 85 5036 5047 10.1128/JVI.02548-10 21389121
24. Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. Brans R, Akhrameyeva NV, Yao F, J Invest Dermatol 2009 129 2470 2479 10.1038/jid.2009.86 19357711
25. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. Brans R, Yao F, BMC Microbiol 2010 10 163 10.1186/1471-2180-10-163 20525279
26. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. Augustinova H, Hoeller D, Yao F, J Virol 2004 78 5756 5765 10.1128/JVI.78.11.5756-5765.2004 15140973 (Pubitemid 38661663)
27. Plasma membrane topology of syncytial domains of herpes simplex virus type 1 glycoprotein K (gK): the UL20 protein enables cell surface localization of gK but not gK-mediated cell-to-cell fusion. Foster TP, Alvarez X, Kousoulas KG, J Virol 2003 77 499 510 10.1128/JVI.77.1.499-510.2003 12477855 (Pubitemid 36004989)
28. The herpes simplex virus type 1 UL20 protein modulates membrane fusion events during cytoplasmic virion morphogenesis and virus-induced cell fusion. Foster TP, Melancon JM, Baines JD, Kousoulas KG, J Virol 2004 78 5347 5357 10.1128/JVI.78.10.5347-5357.2004 15113914 (Pubitemid 38581485)
29. Herpes simplex virus type 1 glycoprotein K and the UL20 protein are interdependent for intracellular trafficking and trans-Golgi network localization. Foster TP, Melancon JM, Olivier TL, Kousoulas KG, J Virol 2004 78 13262 13277 10.1128/JVI.78.23.13262-13277.2004 15542677 (Pubitemid 39507831)
30. The herpes simplex virus UL20 protein functions in glycoprotein K (gK) intracellular transport and virus-induced cell fusion are independent of UL20 functions in cytoplasmic virion envelopment. Melancon JM, Fulmer PA, Kousoulas KG, Virol J 2007 4 120 10.1186/1743-422X-4-120 17996071
31. Functional and physical interactions of the herpes simplex virus type 1 UL20 membrane protein with glycoprotein K. Foster TP, Chouljenko VN, Kousoulas KG, J Virol 2008 82 6310 6323 10.1128/JVI.00147-08 18434401 (Pubitemid 351875110)
32. The Amino Terminus of Herpes Simplex Virus Type-1 (HSV-1) Glycoprotein K (gK) is Required for Virion Entry via The Paired Immunoglobulin-like Type-2 Receptor Alpha (PILRalpha). Chowdhury S, Chouljenko VN, Nadheri M, Kousoulas KG, J Virol 2013 87 3305 3313 10.1128/JVI.02982-12 23302878
33. The amino terminus of herpes simplex virus type 1 glycoprotein K (gK) modulates gB-mediated virus-induced cell fusion and virion egress. Chouljenko VN, Iyer AV, Chowdhury S, Chouljenko DV, Kousoulas KG, J Virol 2009 83 12301 12313 10.1128/JVI.01329-09 19793812
34. The herpes simplex virus type 1 UL20 protein and the amino terminus of glycoprotein K (gK) physically interact with gB. Chouljenko VN, Iyer AV, Chowdhury S, Kim J, Kousoulas KG, J Virol 2010 84 8596 8606 10.1128/JVI.00298-10 20573833
35. A herpes simplex virus 1 (McKrae) mutant lacking the glycoprotein K gene is unable to infect via neuronal axons and egress from neuronal cell bodies. David AT, Saied A, Charles A, Subramanian R, Chouljenko VN, Kousoulas KG, MBio 2012 3 00144-00112
36. The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Mott KR, Chentoufi AA, Carpenter D, BenMohamed L, Wechsler SL, Ghiasi H, Invest Ophthalmol Vis Sci 2009 50 2903 2912 10.1167/iovs.08-2957 19168902
37. A recombinant herpes simplex virus type 1 expressing two additional copies of gK is more pathogenic than wild-type virus in two different strains of mice. Mott KR, Perng GC, Osorio Y, Kousoulas KG, Ghiasi H, J Virol 2007 81 12962 12972 10.1128/JVI.01442-07 17898051 (Pubitemid 350156934)
38. Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection. Ghiasi H, Cai S, Nesburn AB, Wechsler SL, Virology 1996 224 330 333 10.1006/viro.1996.0537 8862430 (Pubitemid 26358131)
39. Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K. Ghiasi H, Slanina S, Nesburn AB, Wechsler SL, J Virol 1994 68 2347 2354 8139020 (Pubitemid 24091913)
40. Herpes simplex virus type 1 gK is required for gB-mediated virus-induced cell fusion, while neither gB and gK nor gB and UL20p function redundantly in virion de-envelopment. Melancon JM, Luna RE, Foster TP, Kousoulas KG, J Virol 2005 79 299 313 10.1128/JVI.79.1.299-313.2005 15596825 (Pubitemid 39648385)
41. CD69 is an immunoregulatory molecule induced following activation. Sancho D, Gomez M, Sanchez-Madrid F, Trends Immunol 2005 26 136 140 10.1016/j.it.2004.12.006 15745855 (Pubitemid 40312520)
42. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL, J Virol 2003 77 4558 4565 10.1128/JVI.77.8.4558-4565.2003 12663762 (Pubitemid 36402805)
43. HSV-1 strain McKrae is more neuroinvasive than HSV-1 KOS after corneal or vaginal inoculation in mice. Wang H, Davido DJ, Morrison LA, Virus Res 2013 173 436 440 10.1016/j.virusres.2013.01.001 23339898
44. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. Chentoufi AA, Binder NR, Berka N, Durand G, Nguyen A, Bettahi I, Maillere B, BenMohamed L, J Virol 2008 82 11792 11802 10.1128/JVI.00692-08 18799581
45. Immune epitope database analysis resource. Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, Lundegaard C, Sette A, Lund O, Bourne PE, et al. Nucleic Acids Res 2012 40 525 W530 10.1093/nar/gks438 22610854
46. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Zammit DJ, Turner DL, Klonowski KD, Lefrancois L, Cauley LS, Immunity 2006 24 439 449 10.1016/j.immuni.2006.01.015 16618602
47. Innate and adaptive immune responses to herpes simplex virus. Chew T, Taylor KE, Mossman KL, Viruses 2009 1 979 1002 10.3390/v1030979 21994578
48. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Shin H, Iwasaki A, Nature 2012 491 463 467 10.1038/nature11522 23075848
49. Sensing herpes: more than toll. Melchjorsen J, Rev Med Virol 2012 22 106 121 10.1002/rmv.716 22020814
50. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Holm CK, Jensen SB, Jakobsen MR, Cheshenko N, Horan KA, Moeller HB, Gonzalez-Dosal R, Rasmussen SB, Christensen MH, Yarovinsky TO, et al. Nat Immunol 2012 13 737 743 10.1038/ni.2350 22706339
51. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, Chouljenko VN, Baghian A, Apetrei C, Marx PA, Kousoulas KG, Vaccine 2009 27 893 903 10.1016/j.vaccine.2008.11.087 19070640